- Email: [email protected]
Glimepride effect compare to glibenclamide on metabolic parameters and insulin resistance in type 2 diabetes mellitus
Abstracts
doi:10.1016/j.ejim.2013.08.237
ID: 370 Glimepride effect compare to glibenclamide on metabolic parameters and insulin resistance in type 2 diabetes mellitus M. Emini Sadiku Internal Diseases, University Clinical Center of Kosova, Pristina, Serbia
Aim: The aim of our study is to assess the improvement of insulin resistance and other metabolic parameters in type 2 diabetic patients treated with glimepiride (GP) compared to glibenclamide (GB). Materials and methods: This single-blind, prospective study included 40 type 2 DM patients (age 55.43 ± 8.3 years, duration of diabetes 3.7 ± 3.3 years) without cardiovascular disease, which were randomly assigned to keep the original GB (n = 20) therapy or switch to GP (n = 20). Except anthropometric parameters, the following laboratory parameters were evaluated after 24 weeks of treatment: fasting venous plasma glucose, lipid profile, HbA1C, insulin, adiponectin and hs-CRP. Results: After treatment, the GP group showed significant differences in anthropometric measurements, hip having decreased from 108.5 ± 6.7 cm to 106.2 ± 6.5 cm (P b 0.01), HbA1C, which decreased from 8.9 ± 1.4% to 8.4% ± 1.2% (P b 0.0001), and HOMA-IR, which decreased from 3.0 ± 1.5 to 1.9 ± 1.4 (P = 0.02), whereas adiponectin increased but not significantly (P = 0.08), and lipid profile did not changed significantly. In the GB group significant differences were observed in HbA1C, decreased from 8.8% ± 1.4% to 8.3% ±1.1% (P b 0.0002), whereas adiponectin decreased from 34.3 ± 22.6 to 20.3 ± 11.3 ng/ml (P = 0.011). No changes for CRP were present in both groups. Conclusions: The present study demonstrates that glimepiride has a good effect on insulin resistance and anthropometric measurements compare to glibenclamide whereas both drugs have same effect HbA1c in type 2 diabetic patients. The impact of glibenclamide on adiponectine is worst compare to glimepiride.
TE
DP
Aims: In this study we decided to analyze the efficacy of combined hypoglycemic therapy based on the intake of incretin mimetic exenatide in patients with diabetes mellitus type 2 complicated by dislipidemy and fatty hepatosis. Material and methods: 30 patients (mean age 60.9 ± 1.2 years) with diabetes mellitus type 2 (mean duration of disease 9.2 ± 1.2 years) were treated with metformin (1500 mg per day), exenatide (20 mg daily intramuscularly), fenofibrate (tricor 145 mg per day) and statin (simvastatin 20 mg daily) for 3 months. Entry criteria were: the presence of dislipidemy and fatty hepatosis, and level of glycated hemoglobin between 6.5 and 11%. Parameters of carbohydrate/lipid metabolism and sonographic hepatic echodensitometry were analyzed before and after treatment. Results: After 3 months of treatment level of fasting plasma glucose decreased significantly on 14.3% (6.3 ± 0.3 mmol/l, p b 0.05), postprandial glucose — on 21.6% (p b 0.05), glycated hemoglobin — on 15.1% (6.2 ± 0.2%, p b 0.05), total cholesterol — on 28.3% (p b 0.01), LDL-C — on 48,3% (p b 0.01), and triglycerides — on 45.7% (p b 0.01). Level of HDL-C increased on 26.8% (p b 0.05). Parameter of hepatic echodencity LA decreased on 44.9% (p b 0.05) and attenuation index — on 17.7% (p b 0.05). Conclusion: 3 months combined therapy with incretin mimetic exenatide, metformin and hypolipidemic drugs in patients with diabetes mellitus type 2 complicated by dyslipidemy and fatty hepatosis can improve parameters of carbohydrate and lipid metabolism and diminish intensity of fatty hepatosis.
OF
Endocrinology, Rostov State Medical University, Rostov-on-Don, Russian Federation
According with the classification of diagnostics used in our hospital, the main admission pathologies were: pneumonia (10.2%), stroke (9.5%) and acute heart failure (7.1%). About 104 patients (5.5%) had their diabetes diagnosed for the first time. The mean length of the hospital stay was 11.97 days, the mortality rate was 13.8%, the readmission 30 days after discharge was 16% and the mortality rate 30 days after discharge was 2.7%. Conclusion: These results reflect our country reality in which concerns the new cases that weren't diagnosed as outpatients. This is very important because it allows a better epidemiologic vigilance and better control of other cardiovascular risk factors. Diabetes has a negative impact on the hospital stay, because it increases the mean duration and mortality. When the disease and the referred comorbilities aren't controlled these patients have a worse prognosis compared to non-diabetic patients.
RO
ID: 346 Results of combined therapy with exenatide, metformin and hypolipidemic drugs in patients with diabetes mellitus type 2 S. Vorobiev, N. Kuzmenko, Z. Gusova, E. Petrovskaya, N. Nelassov, J. Kirtanasov
e95
EC
doi:10.1016/j.ejim.2013.08.236
RR
ID: 367 The burden of diabetes mellitus in an internal medicine inpatient department R. Louro, M. Duarte, N. Vieira, D. Faria, M.J. Grade, P. Magalhães, C. Santos, L. Arez
CO
Internal Medicine Department, Centro Hospitalar do Barlavento Algarvio, Portimão, Portugal
UN
Introduction: The total prevalence of Diabetes Mellitus type 2 (DM 2) in Portugal is 12.7%, 5.5% of which are underdiagnosed. The Internal Medicine Specialist has a crucial role when it comes to identifying new cases in inpatients. The authors want to characterize the population of diabetic patients in an Internal Medicine Service of a tertiary hospital that serves a population of about 166,000 habitants. Material and methods: Retrospective, observational and transversal study, which included all the patients in an Internal Medicine service between 1st January 2009 and 30th July 2012 with DM 2 as a first or already known diagnostic. Demographic and clinical data were analyzed. Results: The number of diabetic patients was 1894, corresponding to 22.6% of the total of inpatients. The mean age was 74.6 years and 50.8% were male. The major comorbilities recorded were: ischemic cardiopathy (14.3%), cerebrovascular disease (24.9%) and chronic renal disease (19.7%). Regarding other cardiovascular risk factors 70% of our diabetic patients had hypertension, 19.3% had a BMI N 30 mg/m2 and 28.6% had high levels of cholesterol.
Keywords: insulin resistance, adiponectin, glimepiride, glibenclamide doi:10.1016/j.ejim.2013.08.238
ID: 380 The prevalence of peripheral arterial disease and associated risk factors in patients with diabetes I.I. Simaa, A.M.S. Sebestyena, F. Stoicescua, M. Jingab,c, I. Dutaa,b, A.E. Cosnitaa, G.A. Dinua, A.I. Pavela, E. Rusua,b, G. Raduliana,b a
IInd Diabetes, Nutrition and Metabolic Diseases Department, Prof. Dr. N.C. Paulescu National Institute of Diabetes, Nutrition and Metabolic Diseases, Bucharest, Romania
doi:10.1016/j.ejim.2013.08.237
ID: 370 Glimepride effect compare to glibenclamide on metabolic parameters and insulin resistance in type 2 diabetes mellitus M. Emini Sadiku Internal Diseases, University Clinical Center of Kosova, Pristina, Serbia
Aim: The aim of our study is to assess the improvement of insulin resistance and other metabolic parameters in type 2 diabetic patients treated with glimepiride (GP) compared to glibenclamide (GB). Materials and methods: This single-blind, prospective study included 40 type 2 DM patients (age 55.43 ± 8.3 years, duration of diabetes 3.7 ± 3.3 years) without cardiovascular disease, which were randomly assigned to keep the original GB (n = 20) therapy or switch to GP (n = 20). Except anthropometric parameters, the following laboratory parameters were evaluated after 24 weeks of treatment: fasting venous plasma glucose, lipid profile, HbA1C, insulin, adiponectin and hs-CRP. Results: After treatment, the GP group showed significant differences in anthropometric measurements, hip having decreased from 108.5 ± 6.7 cm to 106.2 ± 6.5 cm (P b 0.01), HbA1C, which decreased from 8.9 ± 1.4% to 8.4% ± 1.2% (P b 0.0001), and HOMA-IR, which decreased from 3.0 ± 1.5 to 1.9 ± 1.4 (P = 0.02), whereas adiponectin increased but not significantly (P = 0.08), and lipid profile did not changed significantly. In the GB group significant differences were observed in HbA1C, decreased from 8.8% ± 1.4% to 8.3% ±1.1% (P b 0.0002), whereas adiponectin decreased from 34.3 ± 22.6 to 20.3 ± 11.3 ng/ml (P = 0.011). No changes for CRP were present in both groups. Conclusions: The present study demonstrates that glimepiride has a good effect on insulin resistance and anthropometric measurements compare to glibenclamide whereas both drugs have same effect HbA1c in type 2 diabetic patients. The impact of glibenclamide on adiponectine is worst compare to glimepiride.
TE
DP
Aims: In this study we decided to analyze the efficacy of combined hypoglycemic therapy based on the intake of incretin mimetic exenatide in patients with diabetes mellitus type 2 complicated by dislipidemy and fatty hepatosis. Material and methods: 30 patients (mean age 60.9 ± 1.2 years) with diabetes mellitus type 2 (mean duration of disease 9.2 ± 1.2 years) were treated with metformin (1500 mg per day), exenatide (20 mg daily intramuscularly), fenofibrate (tricor 145 mg per day) and statin (simvastatin 20 mg daily) for 3 months. Entry criteria were: the presence of dislipidemy and fatty hepatosis, and level of glycated hemoglobin between 6.5 and 11%. Parameters of carbohydrate/lipid metabolism and sonographic hepatic echodensitometry were analyzed before and after treatment. Results: After 3 months of treatment level of fasting plasma glucose decreased significantly on 14.3% (6.3 ± 0.3 mmol/l, p b 0.05), postprandial glucose — on 21.6% (p b 0.05), glycated hemoglobin — on 15.1% (6.2 ± 0.2%, p b 0.05), total cholesterol — on 28.3% (p b 0.01), LDL-C — on 48,3% (p b 0.01), and triglycerides — on 45.7% (p b 0.01). Level of HDL-C increased on 26.8% (p b 0.05). Parameter of hepatic echodencity LA decreased on 44.9% (p b 0.05) and attenuation index — on 17.7% (p b 0.05). Conclusion: 3 months combined therapy with incretin mimetic exenatide, metformin and hypolipidemic drugs in patients with diabetes mellitus type 2 complicated by dyslipidemy and fatty hepatosis can improve parameters of carbohydrate and lipid metabolism and diminish intensity of fatty hepatosis.
OF
Endocrinology, Rostov State Medical University, Rostov-on-Don, Russian Federation
According with the classification of diagnostics used in our hospital, the main admission pathologies were: pneumonia (10.2%), stroke (9.5%) and acute heart failure (7.1%). About 104 patients (5.5%) had their diabetes diagnosed for the first time. The mean length of the hospital stay was 11.97 days, the mortality rate was 13.8%, the readmission 30 days after discharge was 16% and the mortality rate 30 days after discharge was 2.7%. Conclusion: These results reflect our country reality in which concerns the new cases that weren't diagnosed as outpatients. This is very important because it allows a better epidemiologic vigilance and better control of other cardiovascular risk factors. Diabetes has a negative impact on the hospital stay, because it increases the mean duration and mortality. When the disease and the referred comorbilities aren't controlled these patients have a worse prognosis compared to non-diabetic patients.
RO
ID: 346 Results of combined therapy with exenatide, metformin and hypolipidemic drugs in patients with diabetes mellitus type 2 S. Vorobiev, N. Kuzmenko, Z. Gusova, E. Petrovskaya, N. Nelassov, J. Kirtanasov
e95
EC
doi:10.1016/j.ejim.2013.08.236
RR
ID: 367 The burden of diabetes mellitus in an internal medicine inpatient department R. Louro, M. Duarte, N. Vieira, D. Faria, M.J. Grade, P. Magalhães, C. Santos, L. Arez
CO
Internal Medicine Department, Centro Hospitalar do Barlavento Algarvio, Portimão, Portugal
UN
Introduction: The total prevalence of Diabetes Mellitus type 2 (DM 2) in Portugal is 12.7%, 5.5% of which are underdiagnosed. The Internal Medicine Specialist has a crucial role when it comes to identifying new cases in inpatients. The authors want to characterize the population of diabetic patients in an Internal Medicine Service of a tertiary hospital that serves a population of about 166,000 habitants. Material and methods: Retrospective, observational and transversal study, which included all the patients in an Internal Medicine service between 1st January 2009 and 30th July 2012 with DM 2 as a first or already known diagnostic. Demographic and clinical data were analyzed. Results: The number of diabetic patients was 1894, corresponding to 22.6% of the total of inpatients. The mean age was 74.6 years and 50.8% were male. The major comorbilities recorded were: ischemic cardiopathy (14.3%), cerebrovascular disease (24.9%) and chronic renal disease (19.7%). Regarding other cardiovascular risk factors 70% of our diabetic patients had hypertension, 19.3% had a BMI N 30 mg/m2 and 28.6% had high levels of cholesterol.
Keywords: insulin resistance, adiponectin, glimepiride, glibenclamide doi:10.1016/j.ejim.2013.08.238
ID: 380 The prevalence of peripheral arterial disease and associated risk factors in patients with diabetes I.I. Simaa, A.M.S. Sebestyena, F. Stoicescua, M. Jingab,c, I. Dutaa,b, A.E. Cosnitaa, G.A. Dinua, A.I. Pavela, E. Rusua,b, G. Raduliana,b a
IInd Diabetes, Nutrition and Metabolic Diseases Department, Prof. Dr. N.C. Paulescu National Institute of Diabetes, Nutrition and Metabolic Diseases, Bucharest, Romania